Krystal Biotech, Inc. Capital Expenditures
Krystal Biotech, Inc. (KRYS) reported Capital Expenditures of $10.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-03
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $3.56M, a 87.24% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $7.15M, a 15.22% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $2.14M, a 167.04% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $1.70M, a 62.91% increase year-over-year.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $11.95M, a 182.00% increase from fiscal 2024.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $4.24M, a 64.08% decline from fiscal 2023.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $11.80M, a 77.73% decline from fiscal 2022.
- Krystal Biotech, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $52.98M, a 22.47% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $10.71M 10-Q · filed 2026-08-03 | $12.85M derived: sum of 3 quarters · filed 2026-08-03 | $14.56M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $7.15M 10-Q · filed 2026-05-04 | $9.29M derived: sum of 2 quarters · filed 2026-05-04 | $10.99M derived: sum of 3 quarters · filed 2026-05-04 | $12.89M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.84M derived: sum of 2 quarters · filed 2026-02-17 | $5.75M derived: sum of 3 quarters · filed 2026-08-03 | $11.95M 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.61M derived: sum of 2 quarters · filed 2026-08-03 | $9.81M 10-Q · filed 2025-11-03 | $10.61M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $8.11M 10-Q · filed 2026-08-03 | $8.91M derived: sum of 3 quarters · filed 2026-08-03 | $9.96M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $6.20M 10-Q · filed 2026-05-04 | $7.00M derived: sum of 2 quarters · filed 2026-05-04 | $8.05M derived: sum of 3 quarters · filed 2026-05-04 | $9.18M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $801.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.85M derived: sum of 2 quarters · filed 2026-02-17 | $2.98M derived: sum of 3 quarters · filed 2026-02-17 | $4.24M 10-K · filed 2026-02-17 |
| 2024-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $2.18M derived: sum of 2 quarters · filed 2025-11-03 | $3.44M 10-Q · filed 2025-11-03 | $5.28M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $2.39M 10-Q · filed 2025-08-04 | $4.24M derived: sum of 3 quarters · filed 2026-02-17 | $6.02M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-06 | $3.11M derived: sum of 2 quarters · filed 2026-02-17 | $4.89M derived: sum of 3 quarters · filed 2026-02-17 | $7.68M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.63M derived: sum of 2 quarters · filed 2026-02-17 | $6.42M derived: sum of 3 quarters · filed 2026-02-17 | $11.80M 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $4.57M derived: sum of 2 quarters · filed 2024-11-04 | $9.95M 10-Q · filed 2024-11-04 | $15.17M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $8.17M 10-Q · filed 2024-08-05 | $13.39M derived: sum of 3 quarters · filed 2025-02-19 | $27.44M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $5.38M 10-Q · filed 2024-05-06 | $10.60M derived: sum of 2 quarters · filed 2025-02-19 | $24.65M derived: sum of 3 quarters · filed 2025-02-19 | $41.17M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $19.27M derived: sum of 2 quarters · filed 2025-02-19 | $35.79M derived: sum of 3 quarters · filed 2025-02-19 | $52.98M 10-K · filed 2025-02-19 |
| 2022-09-30 | $14.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $30.57M derived: sum of 2 quarters · filed 2023-11-06 | $47.76M 10-Q · filed 2023-11-06 | $88.64M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $16.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $33.71M 10-Q · filed 2023-08-07 | $74.59M derived: sum of 3 quarters · filed 2024-02-26 | $95.58M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $17.19M 10-Q · filed 2023-05-08 | $58.07M derived: sum of 2 quarters · filed 2024-02-26 | $79.06M derived: sum of 3 quarters · filed 2024-02-26 | $83.05M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $40.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $61.87M derived: sum of 2 quarters · filed 2024-02-26 | $65.86M derived: sum of 3 quarters · filed 2024-02-26 | $68.34M 10-K · filed 2024-02-26 |
| 2021-09-30 | $20.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $24.98M derived: sum of 2 quarters · filed 2022-11-07 | $27.45M 10-Q · filed 2022-11-07 | $34.66M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $6.46M 10-Q · filed 2022-08-08 | $13.67M derived: sum of 3 quarters · filed 2023-02-27 | $17.85M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.47M 10-Q · filed 2022-05-09 | $9.68M derived: sum of 2 quarters · filed 2023-02-27 | $13.86M derived: sum of 3 quarters · filed 2023-02-27 | $15.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $11.39M derived: sum of 2 quarters · filed 2023-02-27 | $13.34M derived: sum of 3 quarters · filed 2023-02-27 | $14.84M 10-K · filed 2023-02-27 |
| 2020-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $6.13M derived: sum of 2 quarters · filed 2021-11-08 | $7.64M 10-Q · filed 2021-11-08 | $9.91M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.45M 10-Q · filed 2021-08-09 | $5.73M derived: sum of 3 quarters · filed 2021-08-09 | $6.91M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $1.51M 10-Q · filed 2021-05-10 | $3.79M derived: sum of 2 quarters · filed 2021-05-10 | $4.96M derived: sum of 3 quarters · filed 2021-05-10 | $6.20M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.45M derived: sum of 2 quarters · filed 2021-03-01 | $4.69M derived: sum of 3 quarters · filed 2021-03-01 | $6.40M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.41M derived: sum of 2 quarters · filed 2020-11-09 | $4.12M 10-Q · filed 2020-11-09 | $5.42M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $2.94M 10-Q · filed 2020-08-07 | $4.25M derived: sum of 3 quarters · filed 2020-08-07 | $5.08M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $1.71M 10-Q · filed 2020-05-04 | $3.01M derived: sum of 2 quarters · filed 2020-05-04 | $3.84M derived: sum of 3 quarters · filed 2020-05-04 | |
| 2018-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $2.14M derived: sum of 2 quarters · filed 2020-03-10 | $2.23M 10-K · filed 2020-03-10 | |
| 2018-09-30 | $832.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $930.00K 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | $98.00K 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $171.00K derived: sum of 2 quarters · filed 2018-11-05 | $203.00K derived: sum of 3 quarters · filed 2018-11-05 | $210.00K 10-K · filed 2018-03-12 |
| 2017-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $44.00K derived: sum of 2 quarters · filed 2018-11-05 | $51.00K 10-Q · filed 2018-11-05 | $60.00K derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $39.00K 10-Q · filed 2018-08-06 | $48.00K derived: sum of 3 quarters · filed 2018-08-06 | |
| 2017-03-31 | $7.00K 10-Q · filed 2018-05-07 | $16.00K derived: sum of 2 quarters · filed 2018-05-07 | ||
| 2016-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $15.00K 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $6.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |